<DOC>
	<DOCNO>NCT02213250</DOCNO>
	<brief_summary>The sample size 12 male Chinese subject base CFDA requirement China PK study support registration China .</brief_summary>
	<brief_title>An Open-Label , Single Dose Pharmacokinetic Study Benefix ( Recombinant Factor IX ) Male Chinese Subjects With Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Male Chinese subject 6 year old ( weight ≥20kg ) moderate severe hemophilia B ( Factor IX activity ≤2 % ) . Subjects receive infusion Factor IX product least 4 day administration BeneFIX Day 1 . Subjects must nonbleeding state administration BeneFIX Day 1 . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) disease clinical finding Screening . Diagnosed bleed disorder addition hemophilia B . Current FIX inhibitor history FIX inhibitor ( define &gt; Upper Limit Normal ( ULN ) report lab ) .</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>